NPFFR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4508281	0.57	14/20
SCHEMBL1981602	0.53	11/20
SCHEMBL3167579	0.60	10/20
SCHEMBL4631287	0.57	10/20
SCHEMBL4502727	0.56	10/20
SCHEMBL3178014	0.67	8/20
SCHEMBL2996293	0.66	7/20
SCHEMBL4630062	0.58	7/20
SCHEMBL4517495	0.57	7/20
SCHEMBL2877082	0.56	7/20
SCHEMBL3958497	0.55	7/20
SCHEMBL2863163	0.54	7/20
SCHEMBL2864930	0.52	7/20
SCHEMBL2348786	0.64	6/20
SCHEMBL3171094	0.60	6/20
SCHEMBL2281940	0.59	6/20
SCHEMBL4511211	0.59	6/20
SCHEMBL3373869	0.58	6/20
SCHEMBL1997960	0.58	6/20
SCHEMBL1770778	0.57	6/20

Clinical trials — most relevant to NPFFR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Adjunct Treatment With Cariprazine for Adults With Attention-deficit/Hyperactivity Disorder	PHASE4	UNKNOWN
Brain Activation and Satiety in Children 2	PHASE3	ACTIVE_NOT_RECRUITING
Effects of Exenatide on Hypothalamic Obesity	PHASE1/PHASE2	COMPLETED
Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia	PHASE2	COMPLETED
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin	PHASE2	UNKNOWN
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Effects of Chimeric Natriuretic Peptide Versus Placebo in Stable Heart Failure and Moderate Renal Dysfunction	PHASE1	WITHDRAWN
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor	PHASE1	COMPLETED
Imaging CRF X NOP Interactions in Alcohol Use Disorder	EARLY_PHASE1	RECRUITING
Relationship of Brain Natriuretic Peptide (BNP) Levels to Cardiac Diagnosis, Operation Performed, Post-operative Course and Outcome	nan	COMPLETED
Acylated Ghrelin Response to Acute Exercise in Obesity	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression	nan	COMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
Dydrogesterone-Primed Ovarian Stimulation Protocol Versus Gonadotropin Releasing Hormone Antagonist Protocol in ICSI	nan	UNKNOWN
In Vitro Studies on Pharmacological Regulation and Genetic Risk Factors of Peripheral Human Nociceptors	nan	COMPLETED
Caffeine Efficacy in ADCY5-related Dyskinesia	nan	UNKNOWN
Transcriptome Sequencing Analysis of Whole Blood From Patients With Trigeminal Neuralgia	nan	UNKNOWN
Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
Affective Touch, Hedonia and Suicidal Behavior	nan	COMPLETED
Acute Intermittent Hypoxia in Traumatic Brain Injury	nan	COMPLETED
Expression and Localization of FP Prostaglandin Receptor in Human Ocular Tissues	nan	UNKNOWN
Multicenter Perioperative Opioid Pharmacogenetic Study	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a NPFFR2 binder may also engage these)

Protein	Name	Similarity
Q924H0	—	0.980	Q924H0 →
P50129	—	0.978	P50129 →
HTR2C	5-hydroxytryptamine receptor 2C	0.977	landscape →
O46635	—	0.977	O46635 →
Q75Z89	—	0.976	Q75Z89 →
P56490	—	0.976	P56490 →
ADRA1A	Alpha-1A adrenergic receptor	0.976	landscape →
P97718	—	0.975	P97718 →
Q5IS66	—	0.974	Q5IS66 →
Q60F97	—	0.974	Q60F97 →
P58308	—	0.974	P58308 →
Q9EQD2	—	0.974	Q9EQD2 →
Q5R4Q6	—	0.974	Q5R4Q6 →
P14842	—	0.974	P14842 →
P18130	—	0.974	P18130 →
P34968	—	0.973	P34968 →
P18599	—	0.973	P18599 →
P43140	—	0.973	P43140 →
P35363	—	0.973	P35363 →
Q9WU25	—	0.972	Q9WU25 →
HTR2A	5-hydroxytryptamine receptor 2A	0.972	landscape →
Q5IS53	—	0.972	Q5IS53 →
P50128	—	0.971	P50128 →
Q9N2A4	—	0.971	Q9N2A4 →
O62809	—	0.971	O62809 →
O02824	—	0.971	O02824 →
CHRM5	Muscarinic acetylcholine receptor M5	0.971	landscape →
P08909	—	0.971	P08909 →
Q5IS98	—	0.970	Q5IS98 →
Q9VNM1	—	0.970	Q9VNM1 →